Tango Therapeutics, Inc. (TNGX)
NasdaqGM · USD · Healthcare · Biotechnology
$22.20 (-4.91%) as of
Key statistics
- Market cap
- 3.74B
- Forward P/E
- -13.17
- EPS (TTM)
- -0.85
- Dividend yield
- 0.00%
- 52-week range
- 7.37 – 34.39
- Beta
- 1.17
- Revenue (TTM)
- 53.81M
- Profit margin
- -229.92%
- Analyst target
- $47.09
- Volume
- 5.37M
About Tango Therapeutics, Inc.
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Boston, MA, United States
- Employees
- 137
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.